Poor Immunogenicity, Not Vaccine Strain Egg Adaptation, May Explain the Low H3N2 Influenza Vaccine Effectiveness in 2012-2013

Sarah Cobey, Sigrid Gouma, Kaela Parkhouse, Benjamin S Chambers, Hildegund C Ertl, Kenneth E Schmader, Rebecca A Halpin, Xudong Lin, Timothy B Stockwell, Suman R Das, Emily Landon, Vera Tesic, Ilan Youngster, Benjamin A Pinsky, David E Wentworth, Scott E Hensley, Yonatan H Grad, Sarah Cobey, Sigrid Gouma, Kaela Parkhouse, Benjamin S Chambers, Hildegund C Ertl, Kenneth E Schmader, Rebecca A Halpin, Xudong Lin, Timothy B Stockwell, Suman R Das, Emily Landon, Vera Tesic, Ilan Youngster, Benjamin A Pinsky, David E Wentworth, Scott E Hensley, Yonatan H Grad

Abstract

Background: Influenza vaccination aims to prevent infection by influenza virus and reduce associated morbidity and mortality; however, vaccine effectiveness (VE) can be modest, especially for subtype A(H3N2). Low VE has been attributed to mismatches between the vaccine and circulating influenza strains and to the vaccine's elicitation of protective immunity in only a subset of the population. The low H3N2 VE in the 2012-2013 season was attributed to egg-adaptive mutations that created antigenic mismatch between the actual vaccine strain (IVR-165) and both the intended vaccine strain (A/Victoria/361/2011) and the predominant circulating strains (clades 3C.2 and 3C.3).

Methods: We investigated the basis of low VE in 2012-2013 by determining whether vaccinated and unvaccinated individuals were infected by different viral strains and by assessing the serologic responses to IVR-165, A/Victoria/361/2011, and 3C.2 and 3C.3 strains in an adult cohort before and after vaccination.

Results: We found no significant genetic differences between the strains that infected vaccinated and unvaccinated individuals. Vaccination increased titers to A/Victoria/361/2011 and 3C.2 and 3C.3 representative strains as much as to IVR-165. These results are consistent with the hypothesis that vaccination boosted cross-reactive immune responses instead of specific responses against unique vaccine epitopes. Only approximately one-third of the cohort achieved a ≥4-fold increase in titer.

Conclusions: In contrast to analyses based on ferret studies, low H3N2 VE in 2012-2013 in adults does not appear to be due to egg adaptation of the vaccine strain. Instead, low VE might have been caused by low vaccine immunogenicity in a subset of the population.

Figures

Figure 1.
Figure 1.
Maximum likelihood phylogeny of hemagglutinin (HA) sequences from 1339 influenza A(H3N2) isolates collected from North America during the 2012–2013 influenza season. Vaccination status of the individuals from whom the isolates were collected is noted (purple = vaccinated; orange = unvaccinated; blank = unknown vaccination status). Amino acid sites in which 20 or more of the 1339 specimens differed from the vaccine strain IVR-165 are noted, with the amino acids colored according to the key and annotated according to their location in HA1, HA2, and predicted epitope sites (A–E). The location from which the isolates were collected is color coded according to the key. Abbreviation: HA, hemagglutinin.
Figure 2.
Figure 2.
Correlations between prevaccination titers (lower left panels, blue) and fold changes in titers (upper right panels, red). Fold changes are defined as the post-vaccination titer divided by the prevaccination titer. Points are semitranslucent; darker points represent multiple individuals. The dotted black line shows the diagonal (1:1) curve. On each plot, the x-axis corresponds to the strain for that column, and the y-axis corresponds to the strain for that row.

References

    1. Rolfes MA, Foppa IM, Garg S, et al. . Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the United States Available at: . Accessed 28 December 2017.
    1. Matias G, Haguinet F, Lustig RL, Edelman L, Chowell G, Taylor RJ. Model estimates of the burden of outpatient visits attributable to influenza in the United States. BMC Infect Dis 2016; 16:641.
    1. Santibanez TA, Zhai Y, O’Halloran A, et al. . Flu Vaccination Coverage, United States, 2016–17 Influenza Season Available at: . Accessed 28 December 2017.
    1. Belongia EA, Simpson MD, King JP, et al. . Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016; 16:942–51.
    1. Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. Lancet Infect Dis 2014; 14:1228–39.
    1. WHO Available at: . Accessed 2 January 2017.
    1. Belongia EA, Kieke BA, Donahue JG, et al. . Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004–2005 season to the 2006–2007 season. J Infect Dis 2009; 199:159–67.
    1. Flannery B, Zimmerman RK, Gubareva LV, et al. . Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014–2015. J Infect Dis 2016; 214:1010–9.
    1. Raymond DD, Stewart SM, Lee J, et al. . Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nat Med 2016; 22:1465–9.
    1. Zost SJ, Parkhouse K, Gumina ME, et al. . Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A 2017; 114:12578–83.
    1. Skowronski DM, Janjua NZ, De Serres G, et al. . Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 2014; 9:e92153.
    1. McLean HQ, Thompson MG, Sundaram ME, et al. . Influenza vaccine effectiveness in the United States during 2012–2013: variable protection by age and virus type. J Infect Dis 2015; 211:1529–40.
    1. Lee J, Boutz DR, Chromikova V, et al. . Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nat Med 2016; 22:1456–64.
    1. Petrie JG, Parkhouse K, Ohmit SE, Malosh RE, Monto AS, Hensley SE. Antibodies against the current influenza A(H1N1) vaccine strain do not protect some individuals from infection with contemporary circulating influenza A(H1N1) virus strains. J Infect Dis 2016; 214:1947–51.
    1. McLean HQ, Thompson MG, Sundaram ME, et al. . Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis 2014; 59:1375–85.
    1. Cobey S, Hensley SE. Immune history and influenza virus susceptibility. Curr Opin Virol 2017; 22:105–11.
    1. Linderman SL, Hensley SE. Antibodies with ‘original antigenic sin’ properties are valuable components of secondary immune responses to influenza viruses. PLoS Pathog 2016; 12:e1005806.
    1. Davenport FM, Hennessy AV, Francis T Jr. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med 1953; 98:641–56.
    1. World Health Organization Available at: . Accessed 3 January 2018.
    1. Davenport FM, Hennessy AV. A serologic recapitulation of past experiences with influenza A; antibody response to monovalent vaccine. J Exp Med 1956; 104:85–97.
    1. Jensen KE, Davenport FM, Hennessy AV, Francis T Jr. Characterization of influenza antibodies by serum absorption. J Exp Med 1956; 104:199–209.
    1. Davenport FM, Hennessy AV. Predetermination by infection and by vaccination of antibody response to influenza virus vaccines. J Exp Med 1957; 106:835–50.
    1. Dinis JM, Florek NW, Fatola OO, et al. . Deep sequencing reveals potential antigenic variants at low frequencies in influenza A virus-infected humans. J Virol 2016; 90:3355–65.
    1. Zhou B, Wentworth DE. Influenza A virus molecular virology techniques. Methods Mol Biol 2012; 865:175–92.
    1. Zhou B, Donnelly ME, Scholes DT, et al. . Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and swine origin human influenza A viruses. J Virol 2009; 83:10309–13.
    1. Edgar RC. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 2004; 5:113.
    1. Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics 2006; 22:2688–90.
    1. Hadfield J, Croucher NJ, Goater RJ, Abudahab K, Aanensen DM, Harris SR. Phandango: an interactive viewer for bacterial population genomics. Bioinformatics 2018; 34:292–293. doi:10.1093/bioinformatics/btx610
    1. Orme D, Freckleton R, Thomas G, et al. . caper: Comparative Analyses of Phylogenetics and Evolution in R. R package version 0.5.2. ed. 2013.
    1. Kannan S, Kossenkov A, Kurupati RK, et al. . A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged. Aging (Albany NY) 2015; 7:1077–85.
    1. Dolfi DV, Mansfield KD, Kurupati RK, et al. . Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans. PLoS One 2013; 8:e77164.
    1. Kurupati RK, Kannan S, Xiang ZQ, et al. . B cell responses to the 2011/12-influenza vaccine in the aged. Aging (Albany NY) 2013; 5:209–26.
    1. Chambers BS, Li Y, Hodinka RL, Hensley SE. Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses. J Virol 2014; 88:10986–9.
    1. Fritz SA, Purvis A. Selectivity in mammalian extinction risk and threat types: a new measure of phylogenetic signal strength in binary traits. Conserv Biol 2010; 24:1042–51.
    1. Hensley SE, Das SR, Bailey AL, et al. . Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 2009; 326:734–6.
    1. Koel BF, Burke DF, Bestebroer TM, et al. . Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 2013; 342:976–9.
    1. Thompson WW, Shay DK, Weintraub E, et al. . Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179–86.
    1. Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997; 87:1944–50.
    1. Fazekas de St G, Webster RG. Disquisitions on original antigenic Sin. II. Proof in lower creatures. J Exp Med 1966; 124:347–61.
    1. Linderman SL, Chambers BS, Zost SJ, et al. . Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Proc Natl Acad Sci U S A 2014; 111:15798–803.
    1. Moody MA, Zhang R, Walter EB, et al. . H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One 2011; 6:e25797.
    1. Li Y, Myers JL, Bostick DL, et al. . Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med 2013; 210:1493–500.
    1. Mosterín Höpping A, McElhaney J, Fonville JM, Powers DC, Beyer WEP, Smith DJ. The confounded effects of age and exposure history in response to influenza vaccination. Vaccine 2016; 34:540–6.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する